Gastric emptying in people with type 2 diabetes taking GLP-1 medicines
Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors Agonists
See if GLP-1 medicines like semaglutide slow stomach emptying in adults with type 2 diabetes and how that may affect anesthesia timing.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 38 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Geneva Academic / other |
| Locations | 1 site (Geneva, Canton of Geneva) |
| Trial ID | NCT07506356 on ClinicalTrials.gov |
What this trial studies
This observational project at Geneva University Hospitals will use gastric ultrasound to measure how much food remains in the stomach of people with type 2 diabetes who have been on GLP-1 analogs for more than three months. Thirty-eight participants will attend three ultrasound visits over a seven-day period to track gastric content after routine meals and fasting. People on insulin, with prior gastric surgery or known gastrointestinal motility disorders, or who cannot lie flat or follow instructions are excluded to keep measurements reliable. The goal is to define how long GLP-1 drugs influence gastric emptying so clinicians can make safer decisions about when to stop these medicines before anesthesia.
Who should consider this trial
Good fit: Adults (≥18) with type 2 diabetes who have been treated with a GLP-1 analog for more than three months, are not on insulin, have BMI ≤40, can lie flat and follow instructions, and can attend three visits at the hospital are ideal candidates.
Not a fit: People on insulin, with prior gastric surgery, known GI motility disorders, hiatal hernia, BMI >40, inability to stop smoking 12 hours before measurements, or inability to lie down or follow instructions are unlikely to be eligible or benefit from this project.
Why it matters
Potential benefit: If successful, the results could give clear guidance on how long to stop GLP-1 medicines before anesthesia to reduce the risk of pulmonary aspiration.
How similar studies have performed: Previous studies have shown that GLP-1 agonists slow gastric emptying, but specific evidence guiding how long to stop these drugs before surgery is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female/ Male of 18 years old or more * With Type 2 Diabetes * Treated with GLP 1 analog for more than 3 months * Signed consent * ASA between I and IV Exclusion Criteria: * Insuline treatment * Gastro intestinal motility disorders * Past gastric surgery * Hiatal hernia * Recent trauma * Inability to be lay down for the exam * Inability to follow the instructions for the exam (language, dementia) * BMI \> 40 * Inability to stop smoking 12h before the measures
Where this trial is running
Geneva, Canton of Geneva
- Hôpitaux Universitaires de Genève — Geneva, Canton of Geneva, Switzerland (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.